Figure 5.

A nonpenetrating scAAV9 lot does not inhibit a penetrating lot. Seventy-day-old mice received an intrathecal injection of scAAV9-CB-GFP (10 μL at 1.7 × 10¹³ vg/mL; lot 4) or the GLP scAAV9-CB-IGF1 (10 μL at 1.4 × 10¹³ vg/mL) spiked with a 1:10 volume of the GFP vector (IGF1-GFP-treated). Approximately 70 days later, the animals were euthanized and the spinal cords were sectioned and stained for GFP. Shown are representative sections of cervical spinal cord from (A) untreated, (B) scAAV9-CB-GFP-treated, and (C) IGF1-GFP-treated mice. IT delivery of the GFP vector resulted in robust transduction of the spinal cord (black stain). Mixing a 1:10 volume of this preparation into the GLP preparation did not inhibit the ability of the GFP vector to transduce the gray matter.